“…Ro3206145 p38α/β 4-Azaindoles For p38α = 10 µM Dapper et al, 2013 Optic neuropathy (Dapper et al, 2013) VX-702 p38α Pyridinecarboxamide For p38α = 20 nM Damjanov et al, 2009 Rheumatoid arthritis (Damjanov et al, 2009) MW-108, MW-181 p38α Pyridazine-3-amine For p38α = 30 nM Watterson et al, 2013 Neuroprotection against neurotoxic insult (Xing et al, 2015) SCIO 469 p38α Indole-3-acetamidehydrochloride For p38α = 9 nM Hideshima et al, 2004 Monoclonal gammopathies (Roccaro et al, 2008), multiple myeloma (Hideshima et al, 2004) BMS 582949 p38α Triazine-6carboxamide For p38α = 13 nM Emami et al, 2015 Arterial inflammation (Emami et al, 2015) Development of isoform-specific compounds was based on more targeted inhibitor design strategies (Lee and Kim, 2017;Rohm et al, 2019). Nevertheless, non-specific effects of pharmacological p38 kinase inhibitors on other kinases or off-target effects, demand more specific targeting of individual p38 kinases.…”